Back

Effect of activation wavefront on electrogram characteristics during ventricular tachycardia ablation

17 March 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Rapid Fire 2: new topics in ablation of ventricular arrhythmias Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2019

About the speaker

Photo
Doctor Claire Martin

Royal Papworth Hospital NHS Foundation Trust, Cambridge (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Pure cardiac magnetic resonance-guided ablation of scar-dependent left ventricular tachycardia.
Doctor D. Soto-Iglesias (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Early outcomes of radiosurgery for refractory ventricular tachycardia using the CyberHeart planning system
Doctor A. Al-Ahmad (Austin, US)
Abstract Slides Video
Presentation thumbnail
Stereotactic radiosurgery for ablation of ventricular tachycardia - procedural aspects and toxicity evaluation
Mr J. Cvek (Ostrava, CZ)
Abstract Slides Video
Presentation thumbnail
Mortality and morbidity reduction after frequent PVC ablation in patients with LV systolic dysfunction
Mr D. Penela (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Dynamic high density mapping of late potentials and late repolarization identifies critical sites for ablation in ventricular tachycardia.
Doctor N. SRINIVASAN (Essex, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Rapid Fire 2: new topics in ablation of ventricular arrhythmias

The Event

Event poster

EHRA 2019

17 March - 19 March 2019
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources